We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+11.92%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$76.2M
Cap. Flow
% of AUM
-39.78%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
D.R. Horton
DHI
|
+$888K |
| 2 |
Lennar Class A
LEN
|
+$880K |
| 3 |
Microchip Technology
MCHP
|
+$860K |
| 4 |
Ametek
AME
|
+$859K |
| 5 |
Home Depot
HD
|
+$853K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steel Dynamics
STLD
|
+$1.62M |
| 2 |
Cheniere Energy
CQP
|
+$1.53M |
| 3 |
STOR
STORE Capital Corporation
STOR
|
+$1.44M |
| 4 |
NOA
North American Construction
NOA
|
+$1.43M |
| 5 |
STR
Sitio Royalties
STR
|
+$1.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INBX
426
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $117K | 0.06% |
4,761
-7,502
| -61% | -$221K |
|
427
Codexis
CDXS
$158M
| $117K | 0.06% |
25,102
+13,323
| +113% | +$73K |
|
428
Inovio Pharmaceuticals
INO
$85.6M
| $117K | 0.06% |
6,242
+197
| +3% | +$4.46K |
|
|
MRSN
429
DELISTED
Mersana Therapeutics
MRSN
| $115K | 0.06% |
785
-617
| -44% | -$104K |
|
430
Nkarta
NKTX
$152M
| $115K | 0.06% |
19,135
+10,559
| +123% | +$107K |
|
431
Allogene Therapeutics
ALLO
$625M
| $114K | 0.06% |
18,097
+6,635
| +58% | +$61.4K |
|
432
CRISPR Therapeutics
CRSP
$4.69B
| $113K | 0.06% |
2,791
+996
| +55% | +$52.8K |
|
433
Blackstone Secured Lending
BXSL
$5.36B
| $112K | 0.06% |
5,029
+353
| +8% | +$8.27K |
|
|
CMPS
434
Compass Pathways
CMPS
$1.47B
| $112K | 0.06% |
13,896
+2,835
| +26% | +$28.4K |
|
|
SRNE
435
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $111K | 0.06% |
125,062
+50,975
| +69% | +$67.6K |
|
436
Caribou Biosciences
CRBU
$146M
| $108K | 0.06% |
17,165
-3,204
| -16% | -$28.5K |
|
|
KLRS
437
Kalaris Therapeutics
KLRS
$80.9M
| $107K | 0.06% |
+909
| New | +$154K |
|
438
ImmunityBio
IBRX
$7.15B
| $105K | 0.06% |
20,782
-14,266
| -41% | -$78.3K |
|
439
C4 Therapeutics
CCCC
$389M
| $101K | 0.05% |
17,102
-2,203
| -11% | -$18.3K |
|
|
FLNA
440
Filana Therapeutics
FLNA
$42M
| $93.8K | 0.05% |
3,175
-1,092
| -26% | -$39.2K |
|
441
Fate Therapeutics
FATE
$275M
| $92K | 0.05% |
9,113
+3,506
| +63% | +$65.8K |
|
442
Arcus Biosciences
RCUS
$3.33B
| $86.2K | 0.05% |
4,166
-902
| -18% | -$24.8K |
|
443
Novavax
NVAX
$1.21B
| $83.6K | 0.04% |
8,129
+5,436
| +202% | +$95.9K |
|
444
American International
AIG
$42.5B
| – | – |
-13,160
| Closed | -$625K |
|
445
Allstate
ALL
$70.6B
| – | – |
-5,863
| Closed | -$730K |
|
446
Amcor
AMCR
$21.2B
| – | – |
-10,751
| Closed | -$577K |
|
447
Advanced Micro Devices
AMD
$700B
| – | – |
-7,460
| Closed | -$473K |
|
448
American Tower
AMT
$83.5B
| – | – |
-2,660
| Closed | -$571K |
|
|
LONA
449
LeonaBio Inc
LONA
$66.1M
| – | – |
-1,301
| Closed | -$39K |
|
450
Berkshire Hathaway Class B
BRK.B
$1.1T
| – | – |
-2,369
| Closed | -$633K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
RC
TSS
Virtus ETF Advisers's Q4 2022 Portfolio in Review
As of Q4 2022, Virtus ETF Advisers held 489 positions worth $191M, down 24% from $251M the previous quarter. Its ten largest holdings account for 5.8% of the portfolio.
Virtus ETF Advisers withdrew a net $76.2M in Q4 2022, closing 46 positions and reducing 226 holdings. Its most notable exit was iShares JPMorgan USD Emerging Markets Bond ETF, an estimated $877K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 19% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in D.R. Horton worth $987K.
- Virtus ETF Advisers's largest Q4 2022 buy was D.R. Horton: 11,078 shares worth $987K.
- Virtus ETF Advisers added most to Qualcomm in Q4 2022, an estimated $271K increase.
- Virtus ETF Advisers's biggest Q4 2022 reduction was Steel Dynamics, cutting an estimated $1.62M.
- Virtus ETF Advisers fully exited iShares JPMorgan USD Emerging Markets Bond ETF in Q4 2022, selling an estimated $877K.
- Virtus ETF Advisers's ten largest holdings make up 5.8% of its $191M portfolio in Q4 2022.
- Virtus ETF Advisers opened 53 new positions and closed 46 in Q4 2022.
- Virtus ETF Advisers's portfolio value fell 24% quarter-over-quarter to $191M.
Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.